Zellulin® ZelluGEN™ is a new cell-identical biopeptide complex clinically proven to promote healthy skin. Zellulin ZelluGEN™ is produced at an ISO22716-certified facility using a novel, sustainable bioprocess with full traceability.

ZelluGEN™ significantly upregulated genes related to healthy extracellular matrix metabolisms in a human skin cell model (HaCaT keratinocyte). The in vitro findings were validated in a randomized, placebo-controlled clinical trial conducted by an independent lab.

Methodology

The clinical trial used an eye cream containing 1% ZelluGEN™ biopeptide complex and the same eye cream without ZelluGEN™ as the placebo. The cohort consisted of 30 healthy Chinese females in the treatment group and 30 in the placebo group, aged 30-55 years (Table 1; mean age: 48.03 in the treatment group, 42.90 in the placebo group).

Table 1. Age distribution of the cohort

Participants applied the eye cream to the eye contour area twice daily for 28 days. Measurements were taken at baseline (D0) and after 28 days (D28).

Evaluation

Skin hydration and transepidermal water loss (TEWL) were measured using a Corneometer CM825 and a Tewameter Tm30, respectively. Skin elasticity and firmness were evaluated with a Cutometer MPA580, and skin ultrasound was performed using a DermaLab Combo. Differences between D0 and D28 values were analyzed using repeated-measures ANOVA. Safety and adverse effects were assessed by a dermatologist at D0 and D28. Self-questionnaires measured user satisfaction.

Key Findings

Skin Hydration: The treatment group showed a significant increase in skin hydration compared to the placebo group. The hydration level increased by 19.38% in the treatment group versus 6.32% in the placebo group, indicating the improved moisturizing efficacy of the product (Fig 1A).

Fig 1. Clinical trial of ZelluGEN™ biopeptide complex eye cream. Individuals were tested for (A) hydration (B) TEWL (C) elasticity (D) firmness and (E) dermal intensity of the skin after 28 days of trial. Asterisks indicate statistical significance (ANOVA) between the treatment and placebo groups. *p < 0.05; **p < 0.01; ***p < 0.001.

TEWL: The treatment group experienced a significant reduction in TEWL, indicating strengthened skin barrier function. The TEWL decreased by 19.49% in the treatment group compared to 3.57% in the placebo group (Fig 1B).

Skin Elasticity: There was a notable increase in skin elasticity in the treatment group, with a 10.44% improvement compared to 2.78% in the placebo group, resulting in better skin bounciness (Fig 1C).

Skin Firmness: The treatment group improved by 19.69% compared to the 8.42% improvement in the placebo group (Fig 1D). The treatment group showed a significant increase in skin firmness and enhanced skin resilience.

Dermal Intensity: The treatment group exhibited an increase in dermal intensity, suggesting higher collagen content (Fig 2). The dermal intensity increased by 10.60% in the treatment group, while the placebo group saw a decrease of 3.94% (Fig 1E). The improvement in skin condition is visually observed (Fig. 3).

Fig 2. Ultrasound analysis of dermal intensity. The treatment group showed an increased protein content after 28 days of trial.

Fig 3. Visual inspection of ZelluGEN biopeptide complex eye cream administration site at the start and end of the trial.

Safety: None of the individuals in the treatment group and the control group has developed adverse reaction to the products.

User Experiences: Subjects in the treatment group reported high satisfaction rates.

• 96.67% felt the product improved skin moisture.
• 100% felt increased skin elasticity.
• 96.67% felt improved skin firmness.
• 96.67% were satisfied with the product's efficacy.
• 93.33% would continue using the product and recommend it to others.

Zellulin ZelluGEN™ is water-soluble and suitable for use as an advanced multifunctional active ingredient within anti-aging formulations. It demonstrated significant clinical efficacy in improving skin hydration, barrier function, elasticity, firmness, and dermal intensity without any adverse effects. The product was well-received by the subjects, with high satisfaction rates and willingness to continue use and recommend to others. The clinical study supports the product's claims of moisturizing, enhancing skin barrier function, and improving skin elasticity and firmness.

Visit our website

Get Information

 

Manufacturer
Avant Proteins Pte. Ltd.
Unit No. 06-03, Tee Yih Jia Food Hub
5 Senoko Road,
Singapore 758137

Contact
sales@zellulin.tech
+65 8758 0863